Polaryx Therapeutics, Inc. Common Stock
PLYXHealthcare|Biotechnology|US
$1.80
+0.06 (+3.45%)
DCF Value
$0.10
Tangible Book / Share
$0.23
Cash / Share
$0.24
Analyst Consensus
Consensus Target
$6.50
Implied Upside
+261.1%
Low Target
$6.00
High Target
$7.00
Price Target Trend
Last Month
—
0 targets
Last Quarter
$6.00
1 target · +233% vs price
Last Year
$6.50
2 targets · +261% vs price
All Time
$6.50
2 targets · +261% vs price
Rating Trend
Feb 26
1 buy · 0 hold · 0 sell
Mar 26
1 buy · 0 hold · 0 sell
Apr 26
1 buy · 0 hold · 0 sell
May 26
1 buy · 0 hold · 0 sell
Jun 26
1 buy · 0 hold · 0 sell
Jul 26
3 buy · 0 hold · 0 sell
Aug 26
4 buy · 0 hold · 0 sell
Sep 26
4 buy · 0 hold · 0 sell
Oct 26
4 buy · 0 hold · 0 sell
Nov 26
4 buy · 0 hold · 0 sell
Recent Price Targets
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.06| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.03 | $-0.04 | — | — |
| May 15, 2026 | $-0.05 | $-0.02 | — | — |
| Mar 24, 2026 | $-0.13 | $-0.02 | — | — |
| Jan 27, 2026 | $-0.03 | — | — | — |
News
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles
Sep 1, 2026globenewswire.com
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today provided an operational readiness update for…
Aug 25, 2026globenewswire.com